News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Eurand (Milan, Italy) (EURX) to Discuss Strategic Decision-Making at BioEurope Spring

3/10/2011 11:09:28 AM

MILAN, Italy, March 9, 2011 – Steve Ellul, Eurand’s Director of Licensing, will discuss aspects of the Company’s growth strategy during the session “Understanding the Drivers for Strategic Decision-Making” at BioEurope Spring in Milan, Italy on Monday, March 14 from 09:00 to10:30 a.m. local time.

The panel of industry experts will provide insight into the critical decisions encountered by growing biotech companies. Acquired by Axcan Intermediate Holdings, Inc. on February 11, 2011, the acquisition is the culmination of a series of events that correlated with Eurand’s growth as it executed its strategic business plan after becoming an independent company in 1999.

Ellul will relate the decisions that enabled Eurand to evolve from a technology and manufacturing partner into a fully integrated, global specialty pharmaceutical company, with a successful IPO in 2007. In late 2009, Eurand launched ZENPEP® (pancrelipase) Delayed-Release Capsules, its first internally developed pharmaceutical product, in the U.S. market. The ZENPEP franchise, including its 5,000-unit dose authorized generic PANCRELIPASE™, gained approximately 20% market share in 12 months.

A Leading Specialty GI Company

“Bio-Europe Spring is really the first opportunity to publicly showcase the combined company to our current and future partners,” noted Stephen Perrett, Vice President of Portfolio Development. “We’re looking forward to the future with the new company, which has a stronger, more diversified product and technology portfolio of in-market products and pipeline candidates.”

The new entity will combine two like-minded companies with complementary gastrointestinal (GI) capabilities and with an expanded global presence to partner and commercialize our portfolio of products for out-licensing.

Now Available for Out-licensing: Diclomax Retard® (diclofenac sodium) Delayed-Release Capsules

Formulated using Eurand’s Diffucaps® delayed-release technology, Diclomax Retard ER provides a once-daily dosing option of the top-prescribed NSAID, improving patient compliance and providing 24 hours of therapeutic effect.

Backed by a CPP from the U.K., this successful brand name and formulation is available for out-licensing in countries worldwide. Learn more:

Pharmaceutical Technologies for Optimal Drug Delivery Solutions

Eurand specializes in product development that leverages its proprietary pharmaceutical technologies. The Company uses these technologies – Customized Drug Release, Tastemasking, Bioavailability Enhancement – to develop novel pharmaceutical and OTC products designed to provide advantages over existing products or to address unmet medical needs.

Contact Steve Ellul for licensing opportunities or to schedule a meeting at BioEurope Spring (+353 (1) 495 3795 or For more information, visit

Read at

comments powered by Disqus